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Abstract:  Classical  swine  fever  (CSF)  remains  one  of  the most  important  transboundary  viral 
diseases of swine worldwide. The causative agent is CSF virus, a small, enveloped RNA virus of the 
genus Pestivirus. Based on partial  sequences,  three genotypes  can be distinguished  that do not, 
however,  directly  correlate with  virulence. Depending  on  both  virus  and  host  factors,  a wide   
range of clinical syndromes can be observed and thus, laboratory confirmation is mandatory. To 




















A binding  legal  framework exists  for  the surveillance and control  in most countries.  Integral 
parts  of  the  control measures  are  timely  and  reliable diagnosis,  stamping  out  of  infected herds, 











Design  of  control measures  and  risk  assessment  depends  on  the  knowledge  of  factors  that 














precursor  protein  by  viral  and  cellular  proteases  results  in  13  mature  proteins,  the   
above‐mentioned structural proteins and non‐structural proteins Npro, p7, NS2‐3, NS2, NS3, NS4A, 
NS4B,  NS5A,  and  NS5B.  The  latter  have  various  functions  in  the  viral  replication,  e.g.,  NS5B 
represents the RNA‐dependent RNA polymerase [23] and NS3 acts as protease [24,25]. 









contact with  the host  cell  is mediated  through  the Erns which  interacts with  glycosaminoglycans 
[10,11]. For receptor binding and subsequent endocytosis,  the E2‐E1 heterodimer  is essential  [12]. 
After fusion of the virus envelope with the endosomal membrane, the virus core is released into the 
cytoplasm [13–15]. Thereafter, viral RNA is released into the cytoplasm and translation takes place. 
The  binding  of  ribosomes  at  the  rough  endoplasmatic  reticulum  is  realized  through  an  internal 
ribosomal entry site (IRES) at the 5′ NTR, which allows a cap‐independent translation [16–18]. The 





























one month under  cold winter  conditions  [38]. Under  laboratory  conditions,  freeze‐thawing has a 
negative impact on viral titers which can however be prevented by some chemical compounds such 
as dimethyl sulfoxide [39]. With regard to pH values, CSFV is relatively stable between pH 5 and 10. 
Half‐lives  at  low pH  levels  are  temperature dependent with mean half‐lives  that  are more  than   
ten‐fold  lower at room  temperature compared  to 4 °C  (70 h at 4 °C compared  to 5 h at 21 °C  for   
pH 3). Overall variability is high and shows some strain dependence [40]. Another important matrix 
is meat or downstream products. Farez and Morley  [30]  report virus survival over years  in meat 
frozen at −70 °C and of days to years in different meat products. Survival of 4.5 years in frozen meat 
was also reported by Edgar (reviewed in the EFSA scientific report 2009, [28]). Curing and smoking 




Classical  swine  fever  virus  strains  can  be  divided  into  three  genotypes with  three  to  four   
sub‐genotypes. The most recently added sub‐genotype 1.4 was only very recently described for CSFV 
strains from Cuba. These strains had so far been placed into sub‐genotype 1.2 but formed a distinct 
cluster when  compared based on  longer genome  fragments,  e.g.,  full‐length E2, Npro, C, E1,  and   









Union  (EU) Reference Laboratory  for CSF nowadays  recommends using  full‐length E2  encoding 
sequences  for  reliable  CSFV  phylogenies  [51].  The  latter  resulted,  e.g.,  in  the  designation  of   
the  above‐mentioned  new  sub‐genotype  1.4.  Full‐length  sequences  are  being  employed  for 




belonged  to one of  the  subgroups within group 2  (2.1, 2.2, or 2.3)  [45,51,57–64] and were  clearly 
distinct from former CSF reference viruses, which belong to group 1 [50,65]. On the global scale, the 
most prevalent genotype over the last decades was undoubtedly genotype 2 [66]. However, all field 






















Figure  1. Global distribution of  classical  swine  fever virus  (CSFV)  sub‐genotypes  (map based on 
Global Administrative Areas (GADM database 2.8; November 2015)). 
European  CSFV  sequences  were  collected  and  made  available  through  the  semi‐public   
CSF‐database  (DB)  at  the  EU  and  OIE  reference  laboratory  for  CSF  in  Hannover,  Germany   
[49,93–95]. Since the Institute of Virology became European Reference Laboratory for CSF more than 
30 years ago, the virus isolates involved in European outbreaks but also other accessible sequence 
























gastrointestinal symptoms, general weakness, and conjunctivitis  [108]. Around  two  to  four weeks 




  In acute‐lethal  courses, death usually occurs 2–4 weeks after CSFV  infection. Mortality  can 
reach up to 100% from 10 to 30 days depending on the age of the animal and the virulence of the 
virus  strain  [65,109–111].  Due  to  the  immunosuppressive  character  of  CSF  infection,  severe 
respiratory and gastrointestinal secondary infections can complicate the disease course and overlay 





In  general,  only  non‐specific  clinical  signs  are  observed  in  infected  animals  like  remittent  fever, 
depression,  wasting  and  diffuse  dermatitis  (see  Figure  3).  It  is  acknowledged  opinion  that  all 
chronically  infected animals will eventually die. However,  they can  live  for month  in which  they 
constantly shed high amounts of virus. Affected animals may develop antibodies that are in some 
cases only  intermittently present  and do not  effect viral  clearance. This,  together with persistent 




















Figure  3.  Chronic  CSFV  infection.  The  incubation  period  is  the  same  as with  the  acute  course. 
However, it may take up to a month until they are truly recognized. Atypical clinical signs can be 
present throughout and until death, occurring up to three months or even  later after the  infection. 
Antibodies can be detected at  low  levels after  two weeks or  later but do usually not persist. Viral 
shedding  is observed  from about  four days post  infection  till  the death of  the animal.  (a) Pigs are 
















even  48  h  after  birth  [124,125].  This was  shown  to  impact  on  the  efficacy  of  vaccines  and may 
complicate control in endemically affected countries. 




















an ulcer;  (e) gallbladder edema;  (f) hemorrhagic  lymph node;  (g) necrotizing  ileocecal valve; and   
(h) splenic infarcts. 
4. Pathogenesis and Immune Responses 
As mentioned  above,  clinical  signs  of CSFV  infections  can vary  considerably  from peracute 
deaths  to unapparent  courses depending on virulence of  the virus  strain  involved  and different 
(partly unknown) host factors [65]. Unspecific clinical signs predominate, and differentiation from 
several other infectious diseases of swine is only possibly based on laboratory diagnosis. Acute‐lethal 
forms  can  be  viral  hemorrhagic  fever‐like  with  severe  thrombocytopenia,  pulmonary  edema, 
petechial bleedings, and  increased vascular  leakage  [130]. Cytokine  involvement  is discussed  for 
many lesions observed in acute CSF [131]. 
Infection  with  CSFV  is  followed  by  primary  replication  in  the  tonsils  and  subsequently   
spread  to  surrounding  lymphoid  tissues  [132].  The  virus  reaches  the  regional  lymph  nodes   
through lymphatic vessels. Here further replication takes place and the virus is spread via blood to 
secondary  replication  sites  such  as  spleen,  bone  marrow,  and  visceral  lymph  nodes  [133–135]. 
Apoptotic  reactions  as  well  as  phagocytic  and  secretory  activation  can  be  observed  in  several 
macrophage  populations  [136–144].  These  activated macrophages  seem  to  play  a  crucial  role  in   
(immuno‐)pathogenesis while direct damage by the virus could be almost excluded for many lesions 
occurring in the course of CSFV infection. Moreover, dendritic cells are targeted and disturbance of 
the  interferon  system  contributes  to  the pathogenesis  [136–140]. There  seems  to  be  a  correlation 
between  high  interferon  (IFN)‐α  in  the  serum  and  disease  severity  and  virulence  of  the  strain 
involved [140,141]. High IFN‐α concentrations are found as early as two days post infection, prior to 











include  damage  of  endothelial  cells,  causal  involvement  of  thrombocytopenia  (and  DIC), 
erythrodiapedesis,  and  capillary  vasodilatation  and  increased  permeability  [146,148,149,152,153]. 
However, several factors remain unclear and studies with different strains have given conflicting results. 
Despite  the  immunopathogenesis  of  most  CSF‐related  lesions,  pigs  recovering  from   









Susceptible  hosts  are  different  members  of  the  Suidae  family,  particularly  domestic  pigs   







Classical  swine  fever  virus  can  be  transmitted  both  horizontally  and  vertically. Horizontal 
transmission takes places through direct or indirect contact between infected and susceptible pigs. 
Important  indirect  routes  include  feeding  of  virus  contaminated  garbage/swill  and  mechanical 
transmission  via  contact  to  humans  or  agricultural  and  veterinary  equipment  [127].  Aerogenic 
transmission was reported under experimental conditions [166–168], and it can probably play a role 
for within herd transmission [169].   
Upon  contact,  infection  usually  occurs  through  the  oronasal  route,  or  less  frequently  via 
conjunctiva,  mucus  membranes,  skin  abrasions,  insemination,  and  the  use  of  contaminated 
instruments  [170–173].  Infected  pigs  show  high‐titer  viremia  and  shed  virus  at  least  from  the 
beginning of clinical disease until death or specific antibodies have developed. The main excretion 
routes are by saliva, lacrimal secretions, urine, feces, and semen [127,135,173]. As mentioned above, 
chronically  infected  pigs  shed  the  virus  continuously  or  intermittently  until  death  [65]. Vertical 
transmission from pregnant sows to fetuses is possible throughout all stages of gestation and can lead 
to persistently infected offspring (see above). 
Classical  swine  fever  affected  wild  boar  populations  can  serve  as  reservoir  of  the  virus   
and present  a  constant  risk  for domestic pigs. Fritzemeier  et  al.  [2]  could  show  that  almost  60%   
of the primary CSF outbreaks in Germany between 1993 and 1998 were linked to infected wild boar. 
This  link  was  particularly  important  for  holdings  with  low  biosecurity  or  problems  in   
biosafety management.   




in affected wild boar populations  rather  than  showing  the  self‐limiting behavior of  the historical 
highly  virulent  CSFV  strains.  It was  discussed whether  these  strains  are  somewhat  the  ideally 
adapted variants of CSFV for long‐term perpetuation in wildlife [92].   











Recently,  field  applicable  RT‐PCRs  [184]  but  also  alternatives  have  been  designed  such  as   





ELISAs  are  recommended  for  the  use  with  herd‐based  testing  only.  While  the  sensitivity  of   
panpesti‐specific  assays  (based  on  the  Erns)  is  usually  at  least  comparable  with  virus  isolation,   
most CSF specific assays lack sensitivity [196]. Serological screening can be performed using different 
commercially available E2 antibody enzyme‐linked  immunosorbent assays  (ELISAs).  In addition, 
neutralization assays allow, to a certain extent, differentiation of pestivirus antibodies and are used 
for confirmation [197]. 





chimeric  vaccines  such  as  “CP7_E2alf”,  target  the  detection  of  antibodies  directed  against 
glycoprotein Erns [196,198,199]. Recently, additional diagnostic tests have been developed. One is a 
double‐antigen ELISA  format  that was recently commercialized [200], another  is an ELISA with a 
screening and a confirmation part [201]: Moreover, a microsphere immunoassay was also developed 
as a confirmatory test [202].   










Highly  efficacious  and  safe  live‐attenuated  CSF  vaccines  have  existed  for  decades  [160].   
The  underlying  virus  strains  (e.g.,  the C‐strain  of CSFV,  the Lapinized Philippines Coronel,  the 
Thiverval or the Japanese guinea‐pig exaltation negative GPE strain) were attenuated through serial 
passages in animals (rabbits) or cell culture. These vaccines have been implemented in mandatory 
control programs  that  led,  together with  strict hygiene measures,  to  the  eradication of CSF  from 
several  regions  of  the world  [213]. At  this  time,  they  are  still  in  use  in  several Asian  countries 
including  China  [84],  countries  of  South  and  Central America,  Trans‐Caucasian  Countries,  and 
Eastern  Europe  (see  Table  1).  In  2016,  22  countries  officially  reported  mandatory  vaccination 
campaigns (OIE WAHIS [214]).   































In addition,  these vaccines were also adapted  to a bait  format  for oral  immunization of wild   
boar  [6,215,216] and were  recently explored  for  the vaccination of domestic pigs under backyard 
conditions  [217–219]. While  these  vaccines  usually  have  outstanding  virtues  in  terms  of  onset, 






attenuated vaccines, only DIVA vaccines are considered a  feasible option  for domestic pigs  [224].   







that  would  ideally  answer  all  demands  with  regard  to  safety,  efficacy,  DIVA  potential,  and 
marketability [238]. Among the concepts that have been investigated are different vector vaccines based 



































































21. Wiskerchen, M.; Belzer,  S.K.; Collett, M.S. Pestivirus gene  expression: The  first protein product of  the 
bovine viral diarrhea virus large open reading frame, p20, possesses proteolytic activity. J. Virol. 1991, 65, 
4508–4514. 
22. Lackner,  T.;  Müller,  A.;  Pankraz,  A.;  Becher,  P.;  Thiel,  H.J.;  Gorbalenya,  A.E.;  Tautz,  N.  Temporal 
modulation of an autoprotease is crucial for replication and pathogenicity of an rna virus. J. Virol. 2004, 78, 
10765–10775. 


















































of  classical  swine  fever  virus: Recent  isolates  branched  away  from  historical  and  vaccine  strains. Vet. 
Microbiol. 2008, 127, 286–299. 
47. Jiang, D.L.; Liu, G.H.; Gong, W.J.; Li, R.C.; Hu, Y.F.; Tu, C.; Yu, X.L. Complete genome sequences of classical 
























56. Björklund, H.; Lowings, P.;  Stadejek, T.; Vilcek,  S.; Greiser‐Wilke,  I.; Paton, D.; Belak,  S. Phylogenetic
comparison and molecular epidemiology of classical swine fever virus. Virus Genes 1999, 19, 189–195.
57. Greiser‐Wilke, I.; Fritzemeier, J.; Koenen, F.; Vanderhallen, H.; Rutili, D.; De Mia, G.M.; Romero, L.; Rosell,




























70. Sandvik,  T.;  Crooke, H.; Drew,  T.W.;  Blome,  S.; Greiser‐Wilke,  I.; Moennig,  V.; Gous,  T.A.; Gers,  S.;
Kitching, J.A.; Buhrmann, G.; et al. Classical swine fever in South Africa after 87 yearsʹ absence. Vet. Rec.
2005, 157, 267.
71. David,  D.;  Edri,  N.;  Yakobson,  B.A.;  Bombarov,  V.;  King,  R.;  Davidson,  I.;  Pozzi,  P.;  Hadani,  Y.;
Bellaiche, M.; Schmeiser, S.; et al. Emergence of classical swine fever virus in Israel in 2009. Vet. J. 2011, 190,
e146–e149.




















78. Sarma, D.K.; Mishra, N.; Vilcek,  S.;  Rajukumar, K.;  Behera,  S.P.; Nema,  R.K.; Dubey,  P.; Dubey,  S.C. 
























































100. Tamura,  T.;  Sakoda, Y.; Yoshino,  F.; Nomura,  T.; Yamamoto, N.;  Sato, Y.; Okamatsu, M.; Ruggli, N.;   
Kida, H. Selection of classical swine fever virus with enhanced pathogenicity reveals synergistic virulence 
determinants in E2 and NS4B. J. Virol. 2012, 86, 8602–8613.   






103. Sainz,  I.F.; Holinka, L.G.; Lu, Z.; Risatti, G.R.; Borca, M.V. Removal of a N‐linked glycosylation  site of 




























boar  (Sus  scrofa)—Experimental  infections  and viral persistence. Dtsch. Tierarztl. Wochenschr.  1995,  102,   
381–384.   
114. Kaden, V.; Steyer, H.; Schnabel,  J.; Bruer, W. Classical  swine  fever  (CSF)  in wild boar: The  role of  the 
















transmission  of  hog  cholera  virus  in  pigs.  II.  Immunopathological  findings  in  the  fetus.  Zentralbl.
Veterinarmed. B 1980, 27, 243–252.
120. Overby, E.; Eskildsen, M. Transplacental Infection in Susceptible Gilts after Inoculation with: I. Lapinized Swine




























































of  cell  death‐related  IFN  stimulated  genes  (ISG)  differentiates  highly  from moderately  virulent CSFV 
strains. Vet. Res. 2010, 41, 7. 
143. Pauly,  T.; König, M.;  Thiel, H.J.;  Saalmüller, A.  Infection with  classical  swine  fever  virus:  Effects  on 
phenotype and immune responsiveness of porcine T lymphocytes. J. Gen. Virol. 1998, 79, 31–40. 
144. Summerfield, A.; Knoetig, S.M.; Tschudin, R.; McCullough, K.C. Pathogenesis of granulocytopenia and 
















P.P.  Classical  swine  fever  virus  induces  proinflammatory  cytokines  and  tissue  factor  expression  and 
inhibits  apoptosis  and  interferon  synthesis during  the  establishment  of  long‐term  infection  of porcine 
vascular endothelial cells. J. Gen. Virol. 2004, 85, 1029–1037. 
152. Gomez‐Villamandos,  J.C.; Ruiz‐Villamor, E.; Bautista, M.J.; Quezada, M.;  Sanchez, C.P.;  Salguero,  F.J.; 
Sierra, M.A. Pathogenesis of classical swine  fever: Renal haemorrhages and erythrodiapedesis.  J. Comp. 
Pathol. 2000, 123, 47–54. 
























Rodriguez,  F.; Domingo, M.,  et  al.  Interferon‐γ  induction  correlates with  protection  by DNA  vaccine
expressing E2 glycoprotein against classical swine  fever virus  infection  in domestic pigs. Vet. Microbiol.
2010, 142, 51–58.
163. Ganges, L.; Barrera, M.; Nunez,  J.I.; Blanco,  I.;  Frias, M.T.; Rodriguez,  F.;  Sobrino,  F. A DNA  vaccine









167. Weesendorp, E.; Landman, W.J.;  Stegeman, A.; Loeffen, W.L. Detection  and  quantification  of  classical
swine fever virus in air samples originating from infected pigs and experimentally produced aerosols. Vet.
Microbiol. 2008, 127, 50–62.







































of classical swine  fever virus by RT‐PCR with a  fluorogenic probe  (TaqMan).  J. Virol. Methods 1998, 72,   
125–135. 
181. Paton, D.J.; McGoldrick, A.; Belak, S.; Mittelholzer, C.; Koenen, F.; Vanderhallen, H.; Biagetti, M.; De Mia, 
G.M.;  Stadejek, T.; Hofmann, M.A.;  et  al. Classical  swine  fever  virus: A  ring  test  to  evaluate RT‐PCR 
detection methods. Vet. Microbiol. 2000, 73, 159–174. 
182. Paton,  D.J.;  McGoldrick,  A.;  Bensaude,  E.;  Belak,  S.;  Mittelholzer,  C.;  Koenen,  F.;  Vanderhallen,  H.;   
Greiser‐Wilke, I.; Scheibner, H.; Stadejek, T.; et al. Classical swine fever virus: A second ring test to evaluate 
RT‐PCR detection methods. Vet. Microbiol. 2000, 77, 71–81. 

















189. Zhang, X.J.; Han, Q.Y.; Sun, Y.; Belak, S.; Liu, L.; Qiu, H.J. Development of a  loop‐mediated  isothermal 
amplification  for visual detection of  the HCLV vaccine  against  classical  swine  fever  in China.  J. Virol. 
Methods 2011, 171, 200–205. 





a primer‐probe energy  transfer real‐time PCR assay  for detection of classical swine  fever virus.  J. Virol. 
Methods 2010, 168, 259–261. 























201. Aebischer,  A.;  Müller,  M.;  Hofmann,  M.A.  Two  newly  developed  Erns‐based  ELISAs  allow  the
differentiation  of  classical  swine  fever  virus‐infected  from  marker‐vaccinated  animals  and  the
discrimination of pestivirus antibodies. Vet. Microbiol. 2013, 161, 274–285.
202. Xia, H.; Harimoorthy, R.; Vijayaraghavan, B.; Blome, S.; Widen, F.; Beer, M.; Belak, S.; Liu, L. Differentiation
of classical swine  fever virus  infection  from CP7_E2alf marker vaccination by a multiplex microsphere
immunoassay. Clin. Vaccine. Immunol. 2015, 22, 65–71.
203. Huang, Y.L.; Pang, V.F.; Pan, C.H.; Chen, T.H.; Jong, M.H.; Huang, T.S.; Jeng, C.R. Development of a reverse



























212. Prickett,  J.R.;  Zimmerman,  J.J.  The  development  of  oral  fluid‐based  diagnostics  and  applications  in
veterinary medicine. Anim. Health Res. Rev. 2010, 11, 207–216.
213. Greiser‐Wilke,  I.;  Moennig,  V.  Vaccination  against  classical  swine  fever  virus:  Limitations  and  new
strategies. Anim. Health Res. Rev. 2004, 5, 223–226.








216. Kaden, V.; Lange, E.; Küster, H.; Müller, T.; Lange, B. An update on  safety  studies on  the  attenuated 



























subunit marker vaccine against  classical  swine  fever after a  single vaccination. Vet. Microbiol. 2001, 78,   
307–317. 
229. de  Smit, A.J.; Bouma, A.;  de Kluijver, E.P.;  Terpstra, C.; Moormann, R.J.  Prevention  of  transplacental 
transmission of moderate‐virulent classical swine fever virus after single or double vaccination with an E2 
subunit vaccine. Vet. Q. 2000, 22, 150–153. 
230. Dewulf,  J.;  Laevens,  H.;  Koenen,  F.;  Vanderhallen,  H.;  Mintiens,  K.;  Deluyker,  H.;  de  Kruif,  A.  An 





























































255. Reimann,  I.; Depner, K.; Trapp,  S.; Beer, M. An  avirulent  chimeric Pestivirus with  altered  cell  tropism
protects pigs against lethal infection with classical swine fever virus. Virology 2004, 322, 143–157.
256. Renson, P.; Le Dimna, M.; Gabriel, C.; Levai, R.; Blome, S.; Kulcsar, G.; Koenen, F.; Le Potier, M.F. Cytokine

















first  trimesters  of  gestation  may  lead  to  resorption  of  the  fetuses  or  abortion,  whereas 
infection at the end of gestation could also lead to the birth of transiently infected piglets or 
stillbirth. The crucial time for the genesis of persistently  infected piglets  is  in mid gestation 
between days 50 and 70 (Kaden et al. 2005; Liess 1987; Stewart, Carbrey, and Kresse 1973). 
Not  all  of  the  exposed  piglets  have  to  be  persistently  infected  and  also  all  other  above 
mentioned  outcomes  are  possible  during  this  time.  However,  the  most  dangerous 
consequence  is  the birth of persistently  infected  (PI) offspring.  These  animals develop  an 
innate  central  immunotolerance due  to  infection  in an early  stage of development of  the 













prevalence of PI animals  is  low on the population  level, their  impact on disease spread and 
maintenance is crucial. For this reason, detection and removal of these animals is an important 
pilar in any BVDV control effort (Lindberg and Houe 2005; Schweizer and Peterhans 2014). The 







(up to 48 hours)  is also able to  induce an  infection course  in piglets that resembles that of 









Directive  2001/89/EC  and  the  diagnostic  manual  accompanying  it  (Commission  Decision 
2002/106/EC)  (European  Commission  2001).  This  legal  framework  was  established  to 
eradicate  CSF  and  to  prevent  the  spread  of  the  disease  in  the  EU.  According  to  these 
regulations, prophylactic vaccination  is prohibited and  in case of detection of CSF, a  strict 











unless  to be  transported  to a  slaughterhouse designated by  the  competent authority and 
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are  traced  and  destroyed  under  official  supervision. All  these  provisions  shall  apply  for  a 














glycoprotein  E2.  The  vaccine  is  safe  but  shows  drawbacks  especially  in  terms  of  early 
protection and protection against vertical transmission (van Oirschot 2003b).  




The  live marker  vaccine  CP7_E2alf  is  a  chimeric  pestivirus,  based  on  the  cytopathogenic 
BVDV‐1 strain CP7 which serves as a backbone in the vaccine virus (Corapi, Donis, and Dubovi 
1988; Reimann et al. 2004; Reimann, Blome, and Beer 2016; Reimann et al. 2010).  In  this 






BVDV  backbone  (in  blue).  The  arrowhead  indicates  the  G479R  mutation  in  BVDV‐Erns,  which  is 






depends  on  specific  and  reliable  detection  systems  of  these  two  antibodies  against  CSFV 
(Schroeder et al. 2012; Pannhorst et al. 2015).   
In  the  licensing  process,  the  safety,  stability  and  efficacy  of  the  vaccine  had  to  be 
demonstrated.  (European  Medicines  Agency  ‐  Committee  for  Medicinal  Products  for 
Veterinary Use 2014; CORDIS 2013). One of the requirements was demonstration of genetic 
stability. The virus presented  itself as highly stable  in vitro and  in vivo. Furthermore, there 
were no indications that the virus is more prone for mutation or genetic recombination than 
its parental viruses (Goller et al. 2015).  





























into  consideration,  was  the  shown  interference  with  the  serological  DIVA  diagnostics, 
especially in regions where pigs are kept in close proximity with cattle.  
In a supplemental study, full protection after oral vaccination was shown three weeks after 
vaccination, whereas  clinical  protection was  already  shown  two weeks  after  vaccination; 
however, the possibility of virus transmission could not be excluded at that time (Blome et al. 
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Differentiating infected from vaccinated
animalsClassical swine fever (CSF) remains as one of the most important infectious diseases of swine. While pro-
phylactic vaccination is usually prohibited in free countries with industrialized pig production, emer-
gency vaccination is still foreseen. In this context, marker vaccines are preferred as they can reduce
the impact on trade.
The live-attenuated Suvaxyn CSF Marker vaccine by Zoetis (based on pestivirus chimera ‘‘CP7_E2alf ”),
was recently licensed by the European Medicines Agency. Its efficacy for the individual animal had been
shown in prior studies, but questions remained regarding protection against transplacental transmission.
To answer this question, a trial with eight pregnant sows and their offspring was performed as prescribed
by the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Six of the sows were intra-
muscularly vaccinated on day 44 of gestation, while the other two remained as unvaccinated controls.
All sows were challenged with the moderately virulent CSFV strain ”Roesrath” and euthanized shortly
before the calculated farrowing date. Sows and piglets were grossly examined and necropsied. Organs
(spleen, tonsil, lymph node, and kidney), EDTA-blood and serum were collected from all animals. All sam-
ples were tested for antibodies against CSFV glycoproteins E2 and Erns as well as CSFV (virus, antigen and
genome). It could be demonstrated that the vaccine complies with all requirements, i.e. no virus was
found in the blood of vaccinated sows and their fetuses, and no antibodies were found in the serum of
the fetuses from the vaccinated sows. All controls were valid.
Thus, it was demonstrated that a single dose vaccination in the sows efficiently protected the offspring
against transplacental infection with a moderately virulent CSFV strain.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
Classical swine fever (CSF) is one of the most important diseases
in swine, with a large impact on pig production worldwide [1].
Because of this, outbreaks are notifiable to the OIE [1]. To control
the disease that can exhibit variable clinical courses, live-
attenuated and E2 subunit vaccines exist and are commercially
available. The former have been used in eradication programs
throughout the world and are still being used in endemically
affected countries [2,3].
In free countries, prophylactic vaccination is now usually
prohibited but emergency vaccination is still foreseen [1]. In thiscontext, marker vaccines are preferred as they can reduce the
impact on trade [4,5].
Recently, pestivirus chimera ‘‘CP7_E2alf” (Suvaxyn CSF Mar-
ker, Zoetis) was licensed by the European Medicines Agency as live
marker vaccine against CSF. Towards filing of the vaccine dossier,
experimental focus was placed on tests that would show suitability
for emergency vaccination scenarios in countries with industrial-
ized pig production, i.e. provision of early protection after single
vaccination [6]. This meant early and harsh challenge in most effi-
cacy tests with highly virulent CSFV strains. Challenge usually hap-
pened before antibodies were detectable. Under these
circumstances, solid protection was shown for the individual ani-
mal (including sows), but transplacental transmission in pregnant
animals could not be prevented in some cases. Due to this, a warn-
ing was included in the summary of product characteristics that
states that sows should not be vaccinated, due to the risk of birth
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www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro-
duct_Information/veterinary/002757/WC500185867.pdf, visited
July 2017). This warning refers to the fact that in-utero infection
with low and moderately virulent CSFV strains can result in what
is referred to as the ‘carrier sow’ syndrome [7–9]. Piglets born to
these sows can be persistently infected while appearing healthy
at the time of farrowing [10,11]. These infections may go unde-
tected for months but are accompanied by constant shedding of
high amounts of virus. The latter serves as a cause for virus
transmission.
Excluding sows from vaccination can be feasible and advisable
in emergency situations, but if the vaccine should be used in
endemically affected countries to control the disease on a longer
term, vaccination of sows is necessary to protect both sows and
piglets [12]. As most virus strains circulating nowadays are moder-
ately virulent [13], protection against these strains is probably
much more relevant than early protection against highly virulent
strains that are no longer circulating.
To test the hypothesis that ” CP7_E2alf ‘‘is able to confer protec-
tion against vertical transmission of a relevant, moderately viru-
lent CSFV strain, an efficacy test (protection against
transplacental infection) was conducted according to the guideli-
nes of the OIE Manual of Diagnostic Tests and Vaccines (OIE Man-
ual, Chapter 2.8.3, paragraph 2.3.3. ii).2. Material and methods
2.1. Experimental design
Following the guidelines of the OIE Manual, eight pregnant
sows and their fetuses were used in this study. The pregnant sows
were purchased from a commercial breeding farm with a high vet-
erinary hygiene standard and brought to the high containment
facilities at the Friedrich-Loeffler-Institut (FLI), Greifswald-Insel
Riems in Germany. All sows were tested to confirm the absence
of pestiviruses and antibodies against pestiviruses prior to the start
of the trial. Upon arrival, the sows were randomly allocated either
to the control group (two sows) or the vaccinated group (six sows).
Sows were provided ad libitum access to water and were fed com-
mercial feed for breeding sows. All applicable animal welfare reg-
ulations, including EU-directive 2010/63/EC and institutional
guidelines, were followed. The animal experiment was approved
by the competent authority (Landesamt für Landwirtschaft,
Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern,
LALLF MV) under reference number 7221.3-1-077/16 (FLI 19/16).
On day 44 of gestation, the sows of the vaccine group were vac-
cinated intramuscularly (deep into the right neck using a 2 mL
single-use syringe and a 20 G needle) with a single dose (1 mL,
105.25 tissue culture infectious doses 50% (TCID50)/mL) of Suvaxyn
CSF Marker, provided by Zoetis (batch T24070) while the control
group remained unvaccinated. Twenty-one days after vaccination,
both groups (vaccine and control group) were challenged oronasal
with 5 mL of challenge material derived from an animal experi-
ment at the FLI where whole blood was collected from swine
infected with CSFV strain ‘‘Roesrath” (genotype 2.3, originating
from Germany 2009, EU reference laboratory data base entry
CSF1045). The blood had been defibrinated, and prepared as chal-
lenge material. The applied dose was 105.25 TCID50 per mL. Vaccine
and challenge virus were back-titrated after administration to con-
firm the titer. Sows of both groups were sampled at seven and nine
days post challenge. Whole blood (with EDTA) and serumwere col-
lected to detect viremia and seroconversion.
Following the OIE guidelines, the sows were humanely eutha-
nized approximately one week prior to farrowing. All sows and42their fetuses (reproductive performance see supplementary table
1) were examined grossly at necropsy. Serum and EDTA-treated
whole blood, as well as samples of tonsil, lymph node, spleen
and kidney were collected from all animals.
2.2. Additional treatments
All sows presented with lameness upon arrival and were trea-
ted with meloxicam, a nonsteroidal anti-inflammatory drug (Meta-
cam, Boehringer Ingelheim, 20 mg/mL). During the study, some
sows developed abscesses on the skin, especially on the ventrum
and on the forelegs. These were cleaned daily and treated with
cod liver oil zinc ointment. In the case of deep scratches and bite
wounds, they were also treated with oxytetracycline spray (Enge-
mycin Spray, MSD, 25 mg/ml).
2.3. Clinical monitoring
Rectal temperatures and clinical scores following the system
proposed by Mittelholzer et al [14] were collected daily to deter-
mine the health status of the sows, especially after the challenge.
Fever was defined as a rectal body temperature of >40 C for two
consecutive days. The observed parameters were liveliness, bear-
ing, breathing, gait, skin, eyes, fecal consistency, and feed intake.
Each was assigned a score from 0 (within normal limits) to 3
(severely abnormal).
2.4. Laboratory tests
2.4.1. Sample preparation and nucleic acid extraction
All laboratory tests were carried out in accordance with the EU
Diagnostic Manual for CSF (Commission Decision 2002/106/EC)
and the Technical Annex accompanying it. To obtain serum, native
blood samples were centrifuged at 2031g for 20 min at room tem-
perature. The resulting serum was aliquoted and stored at 80 C.
All tissue samples were cut in small pieces (3–4 mm) for homoge-
nization with a metal bead in phosphate-buffered saline (PBS). Tis-
sue pieces were homogenized with a TissueLyser (Qiagen). Viral
RNA was extracted using the NucleoMag VET extraction kit
(Macherey-Nagel) with the KingFisher extraction platform
(Thermo Fisher Scientific). An internal control RNA (IC2) was added
to all extractions [15]. Nucleic acids were subsequently tested in
the accredited routine CSFV-specific RT-qPCR that is established
at the Germany National Reference Laboratory for CSF as CSF-
System one [16]. All RT-qPCRs were performed with a Bio-Rad
CFX 96 Real-Time Detection System (Bio-Rad). Results were
recorded as quantification cycle (Cq) values.
Peripheral-blood mononuclear cells (PBMCs) were prepared by
adding 1 mL of dextran sulfate solution (5%) to 5 mL of EDTA-
blood. After one hour at room temperature, the opaque super-
natant was centrifuged at 2000 rpm for 10 min, washed twice with
PBS and finally resuspended in 2 mL of PBS.
2.4.2. Virus isolation
Virus isolation was performed with 100 mL homogenized organ
material or PBMCs by incubation on porcine kidney (PK15) cells in
24-well plates for 72 h. Subsequently, plates were heat fixed and
stained with an indirect immuno-peroxidase staining, using an
anti-CSFV-E2 monoclonal mouse antibody mix and a polyclonal
goat anti-mouse secondary antibody conjugated with horseradish
peroxidase (Thermo Fisher Scientific).
Titrations to confirm the administered vaccine and virus doses
were performed according to standard procedures as endpoint
dilutions on PK15 cells. These titers were also obtained by indirect
immuno-peroxidase staining.
Fig. 1. Organs of one of the fetuses from naïve control sow 4913 with typical CSF signs. Bladder (A) and kidney (B) with petechial hemorrhages. Fetal lymph node (C), enlarged
and hemorrhagic.
Fig. 2. Results of the IDEXX CSFV Antigen ELISA (A) and the IDEXX CSFV E2
antibody ELISA (B) in sows and their fetuses at the end of the trial. The values are
presented as corrected optical densities and percentage of inhibition, respectively.
Control sows are 4913 and 4583, all others belong to the vaccinated group.
Fig. 3. Magnification 40X. Lymph node (A) and spleen (B) of a naïve control fetus 49
from sow 4913 infected with CSFV. Anti-CSFV staining is present within the
mononuclear cells in the germinal centers of the lymph node and white pulp of the
spleen.
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Antigen detection was carried out on all sera using the Herd-
Chek CSFV Ag/Serum ELISA (IDEXX Laboratories) following the
manufacturer’s protocol.
In addition, detection of CSFV E2 specific antibodies was per-
formed using the IDEXX CSFV Ab ELISA (IDEXX Laboratories). CSFV
Erns specific antibodies were detected by the PrioCHECK CSFV Erns
ELISA (Thermo Fisher Scientific) and the Pigtype CSFV Erns ELISA
(Qiagen).
Neutralization peroxidase-linked antibody assays (NPLA) were
also performed to show freedom of antibodies against pestiviruses
using Border disease strain ”Moredun” and Bovine viral diarrhea43strain ”CP7”, respectively, on SFT-R (sheep fetal thymus) and KOP
(bovine esophagus) cells. Neutralizing antibody titers against CSFV
”Roesrath” and ”Alfort/187” were also completed on PK15 cells.
Titers were calculated as 50% neutralization dose (ND50) using
indirect immune peroxidase staining after an incubation of 72 h.
2.4.4. Flow cytometry analyses
To assess the induction of a cellular immune and memory
response of peripheral blood mononuclear cells (PBMCs) EDTA
blood from day seven post challenge was analyzed by flow cytom-
etry as previously described [17]. Briefly, leukocytes were isolated
by density gradient centrifugation using pancoll animal (Pan
Fig. 4. Results of the IDEXX CSFV E2 antibody ELISA (A), the PrioCHECK CSFV Erns antibody ELISA (B) and the pigtype Erns antibody ELISA (C). The values are presented in
percentage of inhibition and S/P ratio (sample-to-positive-control-ratio). Stars represent control sows (Sow 4583 and Sow 4913), vaccinated sows are represented by circles,
squares and triangles.
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antibodies: anti-pig CD4 (mouse IgG2b, clone 74-12-4, in-house)
with secondary anti-mouse IgG2b PerCP (dianova), anti-pig CD8a
(FITC, clone 11/295/33, SouthernBiotech) and anti-pig CD8b
(mouse IgG2a, clone PG164A, in-house) with secondary anti-
mouse IgG2a AlexaFlour647 (dianova). After permeabilization of
cells with the Intracellular Fixation & Permeabilization Buffer Set
(eBioscienceTM) proliferating cells were visualized with Brilliant
VioletTM 420-conjugated anti-human Ki67 antibody (clone B56,
BD Biosciences). Perforin was stained using PE-conjugated anti-
human perforin antibody (clone dG9, BD Biosciences). All analyses
were run on BD Canto II flow cytometer, FACS DIVA (BD Bio-
sciences) and FlowJo software (Tree Star Inc.).2.4.5. Immunohistochemistry
For the detection of viral antigen by immunohistochemistry, tis-
sues were collected, fixed in 10% neutral buffered formalin and
paraffin embedded. Tissue sections were heated to 110 C for 10
min in 10 mM citric buffer (pH 6.0) in a deckloaking chamber.
Anti-CSFV Monoclonal Antibody BIO 275 (BioX diagnostics)
(1:200) and a secondary anti-mouse biotinylated antibody44(1:200) were applied. For a positive control, an RT-qPCR positive
tonsil from a domestic pig infected with CSFV ‘‘Alfort/ 187” was
used. A tonsil from a slaughter pig from the abattoir was used as
a negative control.3. Results and discussion
3.1. Clinical and pathological observations
Throughout the vaccine trial, all sows remained healthy and
showed no fever or other signs of CSF. Two sows developed multi-
ple abscesses, which were not related to CSFV or the vaccine. The
sows of the control group had normal temperatures throughout
the trial and showed only mild depression on day 13 after the
challenge.
The gross observations at necropsy showed no CSF-related
lesions in the vaccinated sows or their fetuses. Some of the fetuses
of the control sows had ‘‘classical” signs of CSF (Fig. 1), including
petechiae in the kidneys and the bladder as well as enlarged and
marbled lymph nodes [18]. Furthermore, skin petechiae could be
seen in some of these fetuses (Fig. 1).
Fig. 5. Antibody responses in neutralization peroxidase linked antibody assays
(NPLA), using the CSFV ‘‘Rösrath” (A) and CSFV ‘‘Alfort/187” (B) as test viruses. Titers
are presented as group mean neutralization doses 50% (ND50).
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Requirements: The test is valid if virus is found in at least 50% of
the fetuses from the control sows (excluding mummified fetuses).
No virus should be found in the blood of vaccinated sows and in
fetuses from vaccinated sows.
All vaccinated sows were negative for CSFV in all performed
tests throughout the trial. In contrast, both control sows were
tested positive for CSFV by RT-qPCR in blood (Cq values 23.5–
31.0), by antigen ELISA in serum (Fig. 2), and by virus isolation
from PBMCs on days seven and nine after challenge. At the end
of the trial, sera of the control sows were negative in the antigen
ELISA again. However, the organ pools of the control sows collected
at the end day were positive in the RT-qPCR but negative by virus
isolation. It has to be noted that the PCR results of the control sows
showed a decrease of Cq-values from day seven to day nine after
challenge infection, indicating that the virus was able to consider-
ably replicate in the unvaccinated sows despite the lack of obvious
clinical signs. The latter underlines the possible impact of moder-
ately virulent CSFV strains when it comes to breeding animals.
Under field conditions, the infection would probably have gone
unnoticed till persistently infected piglets would have spread the
virus.
The samples of the fetuses of the vaccinated sows tested nega-
tive for CSFV in RT-qPCR, antigen ELISA (Fig. 2) and virus isolation.
This was in clear contrast to the samples of the fetuses from the
control sows, as nearly all organ samples were positive in qPCR45(semi-quantitative results are presented in Supplemental Fig. 1)
and virus isolation. Only one mummy and two stillborn piglets of
sow 4583 were negative by virus isolation. Beyond that, all fetuses
from the control sows tested positive with the serum antigen ELISA
(Fig. 2).
Thus, all of the requirements regarding virus detection were ful-
filled, since all of the fetuses of the control group were positive for
viral genome in PCR and viral antigen in ELISA. Furthermore, no
virus (neither viral antigen nor genome) was detected in blood or
organs of the vaccinated sows throughout the whole trial and no
virus (again neither replicating virus nor viral genome) was
detected in the organ pools of their fetuses.
3.3. Supplementary antigen detection in fetal tissues
In fetuses with gross lesions and positive RT-qPCR results,
immunohistochemistry was performed. Positive staining for CSFV
antigen was apparent in the mononuclear phagocytic cells and
lymphocytes of the lymph node, spleen, tonsil, and kidney (see
Fig. 3). Although no RT-qPCR was completed with bone marrow,
liver, and lung, CSFV antigen could also be detected by immunohis-
tochemistry in some fetuses. Faint staining specific for CSFV anti-
gen was also apparent in the extramedullary hematopoietic cells
scattered throughout the liver.
3.4. Antibody detection
Requirement: Antibodies against CSFV should not be found in
the serum of the fetuses from the vaccinated sows.
For samples taken from the sows, antibody ELISAs (IDEXX CSFV
Ab, PrioCHECK CSFV Erns and Pigtype CSFV Erns) were performed on
the day of vaccination (0 dpv), the day of challenge (21 dpv), day
seven and nine after challenge (28 and 30 dpv), and at the end of
the experiment on 65–68 dpv. All sows tested negative in all E2
and Erns antibody ELISAs and also NPLA (see below) prior to vacci-
nation. The control sows remained negative also in the blood sam-
ples from 21, 28 and 30 dpv, but were positive for anti-E2 and Erns
antibodies at the end of the experiment (Fig. 4).
In contrast, all vaccinated sows tested positive (five animals) or
doubtful (one animal) for E2 antibodies by ELISA at the day of chal-
lenge. From 28 dpv onward, all vaccinated sows were positive in
the E2 antibody ELISA. In the Erns ELISAs, on the other hand, the
vaccinated sows tested negative in all samples except on the last
day at 65–68 dpv. Sera collected from the fetuses were tested neg-
ative in all antibody ELISAs.
The results of the ELISAs, particularly the discriminatory Erns
assays, confirm the marker concept of the vaccine. Antibodies
against Erns were only seen after the challenge (Fig. 4) [19].
Sera were also subjected to neutralization assays. On the day of
vaccination, all sows tested negative for neutralizing antibodies
against all tested pestiviruses. The control sows remained negative
for neutralizing antibodies against CSFV strains ‘‘Roesrath” and
‘‘Alfort/187” on 28 and 30 dpv, while all of the vaccinated sows
were positive beginning on 21 dpv and remained positive until
the end of the experiment. On 21 dpv, two of the vaccinated sows
tested negative for neutralizing antibodies against CSFV strain
‘‘Alfort/187”, but tested positive on day 7 and 9 after challenge as
well as on the last day of the experiment (Fig. 5).
In the NPLA, the control sows tested positive for neutralizing
antibodies against CSFV strains ‘‘Alfort/187” and ‘‘Roesrath” on
the last day, but were negative in all earlier samples. All fetuses
tested negative for neutralizing antibodies against both CSFV
strains in NPLA.
Therefore, the requirement regarding the detection of antibod-
ies was fulfilled. The absence of antibodies in the fetuses of the
control sows indicates either acute-lethal or persistent infection.
Fig. 6. Representative dot plots from sow 4913 (naïve sow, upper part of the figure) and sow 4664 (vaccinated sow, lower part of the figure) in flow cytometric analysis of
PBMCs. Comparison of CD4/CD8 double positive T-cells, cytotoxic T-cells (CD8ab), proliferation and perforin production.
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syndrome.
3.5. Flow cytometric analyses of cellular immune response
A flow cytometric analysis of PBMCs from all sows was per-
formed seven days after challenge. Representative dot plots from
sows 4913 (control) and 4664 (immunized) are shown in Fig. 6.
Immunized sows showed an increased frequency of CD4/CD8 dou-
ble positive T-cells, which are known to be mature antigen-
experienced T-cells. In line with this, the overall frequency of
CD8 cells was higher in immunized sows compared to control
sows. The cytotoxic T-cells (CD8ab) were increased in immunized
animals and showed higher capacity to proliferate (Ki67-positive
cells) as well as to produce perforin, which in turn mediates cyto-
toxicity in infected cells. To determine the capacity of antigen-
experienced T-cells from immunized animals further re-
stimulation-studies are needed.
4. Conclusions
It was demonstrated that pregnant sows and their fetuses were
fully protected with a single dose of the DIVA vaccine ‘‘CP7_E2alf”.
Vertical transmission of a relevant, moderately virulent CSFV was
completely prevented. Also in terms of virus detection in control
animals, all requirements of the OIE manual of standards for diag-
nostic tests and vaccines were fulfilled. In addition, reliable and
accurate serological differentiation between infected and vacci-
nated animals was demonstrated. Thus, this study adds to former
safety and efficacy studies of Suvaxyn CSF Marker (Zoetis).
In the context of emergency vaccination, the previous experi-
ence that protection might be incomplete upon early challenge
with highly virulent strains should still be taken into consideration.
The decision to vaccinate sows has to depend upon the risk assess-
ment implemented by the authorities during potential outbreak
situations.
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Supplemental Figures 
Supplemental Figure 1: Results of the qPCR of the samples from the fetuses of the control sows. The 
values are presented as Cq-values in form of a box-plot diagram. 
Supplemental table 1: Fetal counts 
Status Sow No. Piglets Mummies Stillborn Live 
Naive 4913 2 0 0 2 
Naive 4583 22 2 4 16 
Vaccinated 6278 13 0 0 13 
Vaccinated 4664 15 0 0 15 
Vaccinated 4497 24 1 0 23 
Vaccinated 4499 19 0 0 19 
Vaccinated 4708 23 3 0 20 
Vaccinated 4690 15 0 0 15 
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5 Discussion and outlook 
5.1. Discussion 
Given the fact that CSF is still one of the most important diseases of pigs worldwide, 
vaccination is constantly under debate for both endemic and emergency settings. In 
endemically affected countries, vaccination is used to lower the disease burden. Vaccination 
is then embedded into a mandatory control program (Greiser-Wilke and Moennig 2007; Postel 
et al. 2018; van Oirschot 2003a). Under these circumstances, vaccines are usually applied to 
breeding stock and different age classes of weaners or young fattening animals. Emergency 
vaccination in response to massive outbreaks is a tool to prevent further spread of the disease 
and to protect free areas from introduction. Both vaccination to kill and vaccination to live are 
discussed among stakeholders. Yet, emergency vaccination of breeding animals is viewed with 
caution as these animals will remain in the population and may cause diagnostic problems and 
disturb trade. Moreover, old reports of carrier-sow-syndromes in herds that were emergency 
vaccinated in the incubation period exist and created mistrust. In any case, before vaccination 
of breeding animals there has to be a risk assessment based on solid data, especially for new 
marker vaccines such as CP7_E2alf. While studies in reproductive boar were carried out to 
assess the shedding of vaccine virus in semen (Dräger et al., 2016), there were still open 
questions regarding protection against vertical transmission and thus suitability for sow 
vaccination. The latter question was key part of the presented study. 
As mentioned above, the “carrier-sow-syndrome”, resulting from vertical transmission from 
subclinical sows to their fetuses, is the most feared phenomenon in vaccinated sows without 
full protection. It has to be kept in mind that viral persistence happens through 
immunotolerance. The placenta type of pigs prevents the transfer of maternal antibodies and 
other maternal immune components (Bruno Machado Bertasoli 2015; Sinkora and Butler 
2009) and thus, prevention of the initial event, i.e. transplacental transmission and therefore 
infection of the fetus, is the main target.   
Previous studies with the live attenuated C-strain vaccine already investigated the protection 
against transplacental transmission of CSFV. One of these studies investigated the protective 
effect of an oral vaccination of pregnant sows approximately five weeks after insemination. 
Two experiments were carried out, one with a highly virulent and the other with a moderately 
virulent CSFV-strain for challenge in mid-gestation. All fetuses of the vaccinated sows, were 
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virologically and serologically negative, whereas the fetuses of the control sows tested 
positive for CSFV (Kaden et al. 2008). So it was shown, that vaccination with the C-strain 
vaccine protects against transplacental transmission of CSFV. 
In a study conducted with the subunit marker vaccine Porcilis® Pesti full protection against 
transplacental transmission of CSFV could not be shown. The sows were vaccinated two times 
before insemination and developed neutralizing antibodies five weeks after the first 
vaccination. Although the vaccinated sows were protected against a challenge with a low 
virulent CSFV strain, in one out of ten litters fetuses were viraemic and organ samples of 
some of these fetuses were positive for CSFV (Ahrens et al. 2000). In two studies similar results 
were shown with the two vaccines Bayovac CSF Marker and Porcilis® Pesti. It was shown, that 
neither a one shot vaccination (day 46 of gestation) , nor a two shot vaccination (carried out 
25 and 46 days of gestation) were able to completely prevent transplacental transmission of 
CSFV (Depner et al. 2001). Another study also compared a one and two shot vaccination with 
a CSFV E2-subunit vaccine. In this case, vaccination was carried out four weeks before 
insemination and for the twice vaccinated group again two weeks after insemination. The 
sows were challenged with a moderately virulent CSFV-strain six weeks after insemination. 
The fetuses of the twice vaccinated sows were protected against an infection with CSFV, 
whereas in the group of the once vaccinated sows in one out of nine litters viraemic fetuses 
were found (de Smit et al. 2000). Taken together all these studies, performed with first 
generation marker vaccines, showed difficulties in full protection against transplacental 
transmission of CSFV, especially in a scenario with one shot vaccination during pregnancy. 
For CP7_E2alf, unpublished results are included in the vaccine dossier that show lack of 
protection in some cases when a highly virulent CSFV strain was used for early challenge 
(CORDIS 2013). For this reason, a warning was included in the summary of product 
characteristics: “Sows should not be vaccinated, due to the risk of birth of immunotolerant 
persistently infected offspring(European Medicines Agency - Committee for Medicinal 
Products for Veterinary Use 2015).” In our opinion, this warning is an overestimation, as 
infection of the dam with a highly virulent strain would lead to severe clinics in the sow and 
therefore the animal would be recognized as infected with CSFV and removed from the farm. 
Furthermore, a highly virulent strain would normally lead to the death of the fetuses. In all 
these cases, there would be no persistent infection but abortion and stillbirth. In literature, 
only low and moderately virulent strains are able to induce tolerance (Dahle and Liess 1992; 
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Depner et al. 1995; Kern et al. 1999; Moennig, Floegel-Niesmann, and Greiser-Wilke 2003; 
Rossi et al. 2005). Based on this background, it was important to show that vaccination of sows 
could protect the offspring against transplacental infection with one of the recent moderately 
virulent CSFV field strains from Europe which would be likely to generate PI animals. 
The efficacy test presented in this thesis was conducted according to the guidelines for CSF 
vaccines of the OIE Manual of Diagnostic Tests and Vaccines (OIE Manual, Chapter 2.8.3). The 
OIE efficacy testing is based on an emergency scenario with an one shot vaccination during 
pregnancy in a narrow timeframe before mid-gestation when the genesis of PI animals is most 
likely. Since most of the sows nowadays, especially in large breeding farms, are hormonally 
synchronized, it is most likely that the exact date of insemination is known. So the possibility 
to determine an exact vaccination timepoint which does not contain the risk for undetected 
genesis of PI animals is given in most of the breeding facilities. Using the vaccine in a farm with 
no knowledge of the stage of gestation would not be advisable. The worst case scenario would 
be, that despite the succesful vaccination of the sow, PI animals emerge, since the vaccination 
would have been too late for the development of an appropriate immune response of the sow 
to prevent the transmission of virus through the placental barrier. 
In our study eight pregnant sows and their fetuses were used. On day 44 of gestation, six sows 
were vaccinated intramuscularly with a single dose of CP7_E2alf (Suvaxyn® CSF Marker, 
Zoetis), while two sows remained unvaccinated. Twenty-one days after vaccination, all sows 
were challenged with the moderately virulent CSFV strain “Rösrath”.  
These results of the study showed full protection of the vaccinated sows against the challenge 
infection. On the day of the challenge, all vaccinated sows tested positive or at least doubtful 
(one sow) in the performed E2-ELISA and four out of six sows were positive for neutralizing 
antibodies in the performed neutralization peroxidase-linked antibody assays (NPLA). One 
week later, day 28 after vaccination and one week after the challenge, all vaccinated sows 
tested positive for neutralizing antibodies in NPLA and for anti-E2 antibodies in the antibody 
ELISA. These results are the foundation for the protection of the fetuses against transplacental 
transmission of CSFV “Rösrath”. Neutralization through antibodies of the sow and therefore 
prevention of transmission of CSFV across the placental barrier most likely protects the fetuses 
from the infection with CSFV. The immune system of the fetuses would not be able to mount 
an immune response against the virus as shown for the fetuses of the control sows.  
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All samples of the fetuses of the vaccinated sows tested negative for CSFV in RT-qPCR, antigen 
ELISA and virus isolation. The samples of the fetuses of unvaccinated control sows tested 
positive in all those tests, so viral genome and infectious virus was detected in blood and 
organs of these animals. Furthermore, in some of the fetuses of the control group  “classical” 
signs of CSF could be observed. Some had petechiae in the skin, the kidneys and the bladder, 
compared to the animals of the vaccinated group where no signs of infection were found. 
Given the virus detection in many organs of the control piglets, it can be assumed that several 
animals would have been persistently infected.  
An important finding was also, that the unvaccinated sows showed almost no clinical signs but 
shedding and vertical transmission. Thus, the used challenge virus would create a severe, high 
impact problem in the field. Worldwide, the strains of CSFV seem to be developing from high 
virulent to moderately virulent strains (Edwards et al. 2000; Lange et al. 2012). Moderately 
virulent CSFV strains entail different problems than highly virulent strains: an infection with 
those strains can go unnoticed in older animals as it was demonstrated in different studies 
including the presented (Lohse, Nielsen, and Uttenthal 2012; Tarradas et al. 2014).  
These moderately virulent strains are also associated with the recently described phenomon 
of postnatal persistence, a course of the disease where piglets get persistently infected when 
challenged with a moderately virulent CSFV strain in the first 48 hours after birth (Cabezon et 
al. 2015; Munoz-Gonzalez et al. 2015b). The affected animals do not seroconvert but 
constantly shed virus. Given the high viral load in their bodies, CSF vaccination fails completely. 
This is mainly due to superinfection exclusion or interference (Munoz-Gonzalez et al. 2016). 
This scenario was already shown for vaccination with the C-strain vaccine. The persistently 
infected animals were vaccinated six weeks after challenge with a moderately virulent CSFV 
strain but did not develop a specific immune response and  no neutralizing antibodies were 
detected (Munoz-Gonzalez et al. 2015a). The problem of unsuccessful vaccination is mostly of 
importance in endemic countries, where mandatory vaccination is carried out. For 
emergencies it does not seem to play a crucial role but should still be considered because 
excessive monitoring would be implemented in affected areas. Nonetheless, for the 
application of the vaccine in either situation, it has to be tested whether solid protection of 
the sows could prevent postnatal persistence through maternally derived antibodies. First 
results of a corresponding study show that this effect can be achieved by the live marker 
vaccine (Henke et al., manuscript in preparation). The results of this study would influence the 
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decision for utilization of the live marker vaccine CP7_E2alf in an emergency vaccination 
program. With the study presented in this publication it was demonstrated, that it might not 
be necessary to exclude sows and breeding farms from vaccination programs neither in 
emergency situations nor endemically affected countries. These data were generated 
following the official OIE guidelines and provide a very solid experimental basis. With a solid 
and a thoroughly thought through vaccination program it could be beneficial to also include 
breeding farms in areas with high density of pig production.  
However, in the context of emergency vaccination, the previous experience that protection 
might be incomplete upon early challenge with highly virulent strains should still be taken into 
consideration and has to be seen by implementing adapted diagnostic procedures. The 
decision to vaccinate sows therefore has to depend upon the risk assessment implemented 
by the authorities during potential outbreak situations, and this thesis provides the necessary 





is  a  powerful  tool  for  CSF  control  and  could  be  used  for  breeding  farms  if  indicated. 
Vaccination of breeding sows could then also help to overcome additional problems such as 
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eradication programs  still present  in many  countries worldwide. Recently,  the  live marker 
vaccine  “CP7_E2alf”  (Suvaxyn®  CSF  Marker,  Zoetis),  has  been  licensed  by  the  European 
Medicines  Agency.  However,  data  are  still missing  regarding  the  use  on  breeding  farms, 
expecially  in  breeding  sow  herds.  A  major  concern  was  the  protection  against  vertical 
transmission of CSFV. Since  transmission of virus  in mid‐gestation  can  lead  to persistently 
infected offspring,  it was  important to show that the vaccine  is able to protect the fetuses 














Die Klassische Schweinepest (KSP) gehört bis heute zu den wichtigsten Infektionskrankheiten 
im Bereich der Schweineproduktion und ist trotz massiver Bekämpfungsmaßnahmen weltweit 
immer noch in vielen Ländern verbreitet.  
Vor kurzem wurde der Lebendmarkerimpfstoff “CP7_E2alf” (Suvaxyn® CSF Marker, Zoetis) 
nach eingehender Prüfung durch die Europäische Arzneimittel-Argentur (European Medicines 
Agency, EMA) zugelassen. Trotzdem bestehen noch einige Wissenlücken, insbesondere in 
Bezug auf den Einsatz in Zuchtsauenbetrieben. Ein besonderes Augenmerk lag hierbei auf dem 
Schutz vor transplazentarer Übertragung des Virus auf die Föten, da es bei einer solchen 
Übertragung im mittleren Drittel der Trächtigkeit zur Geburt von persistierent infizierten 
Ferkeln kommen kann, welche eine Immuntoleranz gegenüber dem Virus zeigen und es durch 
Ausscheidung unkontrolliert weiterverbreiten können. In der vorliegenden Studie wurde 
geprüft, ob eine Impfung der Muttersau den Fetus vor einer Infektion mit dem Virus der 
Klassichen Schweinepest (KSPV) schützt. Der Versuchsaufbau entsprach den Vorgaben des 
Diagnosehandbuchs der Weltorganisation für Tiergesundheit. Als Material für die 
Belastungsinfektion der Tiere wurde ein aktueller moderat virulenter KSPV-Stamm 
verwendet. 
Es konnte gezeigt werden, dass eine einmalige Impfung der Sau die Föten vor einer Infektion 
mit KSPV schützt. Es konnten kein Virus und keine Antikörper im Blut und den Organen der 
Föten nachgewiesen werden, darüber hinaus wurden alle Tiere der Kontrollgruppe positiv in 
der Virusisolierung und im Genormnachweis getestet. Die gewonnenen Ergebnisse erfüllen 
somit alle Anforderungen des Handbuchs.  
Die in dieser Studie gewonnen Daten zeigen umfassend, dass es nicht unbedingt nötig ist, 
Sauen und Zuchtbetriebe von (Not)-Impfprogrammen auszuschließen.  
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9 Abbreviations  
BVDV  Bovine viral diarrhea virus 
CSF  Classical swine fever 
CSFV  Classical swine fever virus 
DIVA  Differentiating infected from vaccinated animals 
EC  European commission 
ELISA   Enzyme‐linked Immunosorbent Assay 
EMA  European medicine agency  
EU   European Union 
FLI  Friedrich‐Loeffler‐Institut 
KSP  Klassische Schweinepest 
KSPV  Virus der Klassichen Schweinepest 
NPLA  Neutralization peroxidase‐linked antibody assays 
OIE  World Organization for Animal Health 
PI  Persistent infected 
qPCR  Quantitative polymerase chain reaction 
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